Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Research article published in Blood (2006)
Abstract
The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding. A retrospective observational analysis in 181 patients (median age, 67 years) with confirmed HIT treated in routine practice with lepirudin was performed to identify predictive factors for thrombotic and bleeding complications. Lepirudin was administered at a mean (+/- SD) dose of 0.06 +/- 0.04 mg/kg/h (compared with a recommended initial dose of 0.15 mg/kg/h). Mean activated partial thromboplastin time was greater than 1.5 times baseline value in 99.4% of patients. Median treatment duration was 7.7 days. Until discharge from the hospital, 13.8% and 20.4% of patients experienced a thrombotic or a major bleeding event, respectively. On multivariate analysis, mean lepirudin dose was not a significant predictive factor for thrombosis. In contrast, mean lepirudin dose greater than 0.07 mg/kg/h, long duration of lepirudin treatment, and moderate to severe renal impairment were significant positive factors for major bleeding. Overall, these results suggest that the recommended dose of lepirudin in patients with HIT is too high; the use of reduced doses may be safer with regard to bleeding risk and does not compromise antithrombotic efficacy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding.
Why This Matters for Hirudotherapy
This retrospective observational study analyzed 181 patients with confirmed heparin-induced thrombocytopenia (HIT) who were treated with lepirudin in routine clinical practice. The study identified that the recommended initial lepirudin dose of 0.15 mg/kg/h appeared too high, as mean doses greater than 0.07 mg/kg/h, prolonged treatment duration, and moderate-to-severe renal impairment were significant predictors of major bleeding. Reduced doses did not compromise antithrombotic efficacy, suggesting a safer dosing strategy. While lepirudin provides a direct pharmaceutical connection to anticoagulation therapies, the abstract provides no context regarding its biological origins or relation to live leech therapy and crude leech secretome, limiting its relevance strictly to the clinical dosing of this specific drug.
Citation
Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Tardy B et al. · Blood, 2006
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026